Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques.

Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques.

Anti-cancer immunotherapy is rising from a nadir and demonstrating tangible advantages to sufferers. A wide range of approaches are actually employed. We’re invoking antigen (Ag)-specific responses via direct injections of recombinant lentivectors (LVs) that encode sequences for tumor-associated antigens into a number of lymph nodes to optimize immune presentation/stimulation.
Right here we first exhibit the effectiveness and antigen-specificity of this strategy in mice challenged with prostate-specific antigen (PSA)-expressing tumor cells. Subsequent we examined the protection and efficacy of this strategy in two cohorts of rhesus macaques as a prelude to a medical trial utility.
Our vector encodes the cDNA for rhesus macaque PSA and a rhesus macaque cell floor marker to facilitate vector titering and monitoring. We utilized two unbiased injection schemas demarcated by the timing of LV administration. In each cohorts we noticed marked tissue-specific responses as measured by medical evaluations and magnetic resonance imaging of the prostate gland.
Tissue-specific responses had been sustained for as much as six months-the end-point of the research. Management animals immunized towards an irrelevant Ag had been unaffected. We didn’t observe vector unfold in take a look at or management animals or perturbations of systemic immune parameters. This strategy thus gives an “off-the-shelf” anti-cancer vaccine that could possibly be made at giant scale and injected into patients-even on an out-patient foundation.

Intratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Technique for Enhancing the Antitumor Impact of Remedy Composed of Cyclophosphamide and Dendritic Cells.

Vaccination with dendritic cells (DCs) stimulated with tumor antigens can induce particular mobile immune response that acknowledges a excessive spectrum of tumor antigens. Nevertheless, the flexibility of most cancers cells to provide immunosuppressive components drastically decreases the antitumor exercise of DCs.
The principle objective of the research was to enhance the effectiveness of DC-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by utility of lentivectors (LVs)-encoding brief hairpin RNA particular for TGF-β1 (shTGFβ1 LVs). We noticed that s.c. inoculation of each MC38 cells with silenced expression of TGF-β1 (MC38/shTGF-β1) and direct intratumoral utility of shTGFβ1 LVs contributed to discount of suppressor exercise of myeloid cells and Tregs in tumor.
Opposite to expectations, in mice bearing wild tumor, the applying of shTGFβ1 LVs previous to vaccination with bone marrow-derived DC stimulated with tumor antigens (BMDC/TAg) didn’t affect myeloid-derived suppressor cell (MDSC) infiltration into tumor. Because of this, we noticed solely minor MC38 tumor development inhibition (TGI) accompanied by systemic antitumor response activation similar to that obtained for destructive management (shN).
Nevertheless, when the proposed scheme was complemented by pretreatment with a low dose of CY, we seen excessive MC38 TGI along with decreased variety of MDSCs in tumor and induction of Th1-type response. Furthermore, in each schemes of remedy, LVs (shTGFβ1 in addition to shN) induced excessive inflow of CTLs into tumor related in all probability with the viral antigen introduction into tumor microenvironment. Concluding, the applying of shTGFβ1 LVs alone or together with DC-based vaccines just isn’t adequate for long-lasting elimination of suppression in tumor.
Nevertheless, simultaneous discount of TGF-β1 in tumor microenvironment and its transforming by pretreatment with a low dose of CY facilitates the settlement of peritumorally inoculated DCs and helps them in restoration and activation of a potent antitumor response.
Recombinant lentiviral vectors (LVs) are extremely efficient vaccination autos that elicit protecting T cell immunity in illness fashions. Dendritic cells (DCs) purchase antigen at websites of vaccination and migrate to draining lymph nodes, the place they prime vaccine-specific T cells. The efficiency with which LVs activate CD8+ T cell immunity has been attributed to the transduction of DCs on the immunization website and sturdy presentation of LV-encoded antigens.
Nevertheless, it’s not recognized how LV-encoded antigens proceed to be offered to T cells as soon as straight transduced DCs have turned over. Right here, we report that LV-encoded antigen is effectively cross-presented by DCs in vitro. We have now additional exploited the temporal depletion of DCs within the murine CD11c.DTR (diphtheria toxin receptor) mannequin to exhibit that repopulating DCs that had been absent on the time of immunization cross-present LV-encoded antigen to T cells in vivo.
Oblique presentation of antigen from transduced cells by DCs is adequate to prime practical effector T cells that management tumor development. These information recommend that DCs cross-present immunogenic antigen from LV-transduced cells, thereby facilitating extended activation of T cells within the absence of circulating LV particles. These are findings which will affect on the longer term design of LV vaccination methods.

Optimization of a Genome-Broad Disordered Lentivector-Primarily based Brief Hairpin RNA Library.

 

To acquire an entire genome library that suppresses the full variety of human mRNAs, lentiviral vector constructs and a brief hairpin RNA (shRNA) expression cassette had been optimized. The optimization of the vector elevated the virus titer in preparations by 15-20 instances. A easy shRNA construction with a 21-bp stem proved to be the simplest.
Lentivector-based shRNA expression constructs had been obtained through the use of puro(R), copGFP, or H-2K(okay) as a selectable marker. The effectivity of the optimized library was demonstrated when screening for shRNAs reactivating the tumor suppressor p53 in HeLa cells. Cells carried a reporter assemble guaranteeing p53-responsive synthesis of a fluorescent protein, which allowed choice of cells with reactivated p53 by stream cytometry.

Injectable alginate hydrogel for enhanced spatiotemporal management of lentivector supply in murine skeletal muscle.

Hydrogels are an particularly interesting class of biomaterials for gene supply autos as they are often launched into the physique with minimally invasive procedures and are sometimes utilized in tissue engineering and regenerative medication methods. On this research, we present for the primary time using an injectable alginate hydrogel for managed supply of lentivectors within the skeletal muscle of murine hindlimb. We suggest to change the discharge charges of lentivectors via manipulation of the molecular weight distribution of alginate hydrogels.
The discharge of lentivector was examined utilizing two completely different ratios of high and low molecular weight (MW) alginate polymers (75/25 and 25/75 low/excessive MW). The interdependency of lentivector launch fee and alginate degradation fee was assessed in vitro. Lentivector-loaded hydrogels maintained transduction potential for as much as one week in vitro as demonstrated by the continuous transduction of HEK-293T cells.

CENPK Antibody

ABD9059 100 ug
EUR 525.6

CENPK Antibody

1-CSB-PA005214ESR1HU
  • EUR 266.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against CENPK. Recognizes CENPK from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IP; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200, IP:1:200-1:2000

CENPK Antibody

1-CSB-PA005214ESR2HU
  • EUR 266.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against CENPK. Recognizes CENPK from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

CENPK Antibody

E19-9059-1 50ug/50ul
EUR 145
Description: Available in various conjugation types.

CENPK Antibody

E19-9059-2 100ug/100ul
EUR 225
Description: Available in various conjugation types.

CENPK Antibody

DF9059 100ul
EUR 280
Description: Human,Mouse

CENPK Antibody

DF9059-100ul 100ul
EUR 280

CENPK Antibody

DF9059-200ul 200ul
EUR 350

Cenpk sgRNA CRISPR Lentivector set (Rat)

K6564001 3 x 1.0 ug
EUR 406.8

CENPK sgRNA CRISPR Lentivector set (Human)

K0432501 3 x 1.0 ug
EUR 406.8

Cenpk sgRNA CRISPR Lentivector set (Mouse)

K3101501 3 x 1.0 ug
EUR 406.8

CENPK Rabbit pAb

A7627-100ul 100 ul
EUR 369.6

CENPK Rabbit pAb

A7627-200ul 200 ul
EUR 550.8

CENPK Rabbit pAb

A7627-20ul 20 ul
EUR 219.6

CENPK Rabbit pAb

A7627-50ul 50 ul
EUR 267.6

CENPK Rabbit pAb

E2517627 100ul
EUR 225
Description: Available in various conjugation types.

CENPK cloning plasmid

CSB-CL005214HU-10ug 10ug
EUR 279.6
Description: A cloning plasmid for the CENPK gene.

CENPK Blocking Peptide

DF9059-BP 1mg
EUR 234

Cenpk sgRNA CRISPR Lentivector (Rat) (Target 1)

K6564002 1.0 ug DNA
EUR 184.8

Cenpk sgRNA CRISPR Lentivector (Rat) (Target 2)

K6564003 1.0 ug DNA
EUR 184.8

Cenpk sgRNA CRISPR Lentivector (Rat) (Target 3)

K6564004 1.0 ug DNA
EUR 184.8

CENPK Protein Vector (Rat) (pPM-C-HA)

PV259396 500 ng
EUR 723.6

CENPK Conjugated Antibody

C45679 100ul
EUR 476.4

CENPK Polyclonal Antibody

ABP58115-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of CENPK from Human, Mouse. This CENPK antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CENPK protein at amino acid sequence of 50-130

CENPK Polyclonal Antibody

ABP58115-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of CENPK from Human, Mouse. This CENPK antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CENPK protein at amino acid sequence of 50-130

CENPK Polyclonal Antibody

ABP58115-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of CENPK from Human, Mouse. This CENPK antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CENPK protein at amino acid sequence of 50-130

CENPK Polyclonal Antibody

ES9253-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against CENPK from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

CENPK Polyclonal Antibody

ES9253-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against CENPK from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

CENPK Polyclonal Antibody

E11-200307 100ug/100ul
EUR 225
Description: Available in various conjugation types.

CENPK Polyclonal Antibody

E97627 100ul
EUR 225
Description: Available in various conjugation types.

CENPK Protein Vector (Rat) (pPB-C-His)

PV259394 500 ng
EUR 723.6

CENPK Protein Vector (Rat) (pPB-N-His)

PV259395 500 ng
EUR 723.6

CENPK Protein Vector (Rat) (pPM-C-His)

PV259397 500 ng
EUR 723.6

CENPK sgRNA CRISPR Lentivector (Human) (Target 1)

K0432502 1.0 ug DNA
EUR 184.8

CENPK sgRNA CRISPR Lentivector (Human) (Target 2)

K0432503 1.0 ug DNA
EUR 184.8

CENPK sgRNA CRISPR Lentivector (Human) (Target 3)

K0432504 1.0 ug DNA
EUR 184.8

Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3101502 1.0 ug DNA
EUR 184.8

Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3101503 1.0 ug DNA
EUR 184.8

Cenpk sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3101504 1.0 ug DNA
EUR 184.8

CENPK Protein Vector (Human) (pPM-C-HA)

PV009011 500 ng
EUR 394.8

CENPK Protein Vector (Mouse) (pPM-C-HA)

PV164656 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPM-C-HA)

PV164660 500 ng
EUR 723.6

CENPK Protein Vector (Human) (pPB-C-His)

PV009009 500 ng
EUR 394.8

CENPK Protein Vector (Human) (pPB-N-His)

PV009010 500 ng
EUR 394.8

CENPK Protein Vector (Human) (pPM-C-His)

PV009012 500 ng
EUR 394.8

CENPK Protein Vector (Mouse) (pPB-C-His)

PV164654 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPB-N-His)

PV164655 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPM-C-His)

PV164657 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPB-C-His)

PV164658 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPB-N-His)

PV164659 500 ng
EUR 723.6

CENPK Protein Vector (Mouse) (pPM-C-His)

PV164661 500 ng
EUR 723.6

Mouse CENPK shRNA Plasmid

20-abx975206
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Human CENPK shRNA Plasmid

20-abx961921
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

CENPK Recombinant Protein (Rat)

RP194543 100 ug Ask for price

CENPK Recombinant Protein (Human)

RP006757 100 ug Ask for price

CENPK Recombinant Protein (Mouse)

RP123488 100 ug Ask for price

CENPK Recombinant Protein (Mouse)

RP123491 100 ug Ask for price

CENPK ELISA Kit (Human) (OKCA00632)

OKCA00632 96 Wells
EUR 999.6
Description: Description of target: Component of the CENPA-CAD (nucleosome distal) complex, a complex recruited to centromeres which is involved in assembly of kinetochore proteins, mitotic progression and chromosome segregation. May be involved in incorporation of newly synthesized CENPA into centromeres via its interaction with the CENPA-NAC complex. Acts in coordination with CASC5/KNL1 to recruit the NDC80 complex to the outer kinetochore.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 5.8 pg/mL

Human CENPK Protein Lysate 20ug

IHUCENPKPLLY20UG each
EUR 213
Description: Human CENPK Protein Lysate 20ug

Human Centromere protein K (CENPK)

1-CSB-EP005214HU
  • EUR 606.00
  • EUR 318.00
  • EUR 2192.40
  • EUR 919.20
  • EUR 1461.60
  • EUR 402.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Centromere protein K(CENPK) expressed in E.coli

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6564005 3 x 1.0 ug
EUR 451.2

Centromere Protein K (CENPK) Antibody

20-abx149226
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

Centromere Protein K (CENPK) Antibody

20-abx321953
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Centromere Protein K (CENPK) Antibody

20-abx321954
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

Centromere Protein K (CENPK) Antibody

20-abx006672
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

CENPK sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0432505 3 x 1.0 ug
EUR 451.2

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3101505 3 x 1.0 ug
EUR 451.2

CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV664129 1.0 ug DNA
EUR 818.4

CENPT Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV664133 1.0 ug DNA
EUR 818.4

CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV661477 1.0 ug DNA
EUR 1626

CENPI Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV661481 1.0 ug DNA
EUR 1626

CENPQ Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV662119 1.0 ug DNA
EUR 616.8

CENPQ Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV662123 1.0 ug DNA
EUR 616.8

CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV669043 1.0 ug DNA
EUR 818.4

CENPL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV669047 1.0 ug DNA
EUR 818.4

CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV669049 1.0 ug DNA
EUR 818.4

CENPL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV669053 1.0 ug DNA
EUR 818.4

CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV700843 1.0 ug DNA
EUR 616.8

CENPW Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV700847 1.0 ug DNA
EUR 616.8

CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV662647 1.0 ug DNA
EUR 818.4

CENPN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV662651 1.0 ug DNA
EUR 818.4

CENPC1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV628759 1.0 ug DNA
EUR 1626

CENPC1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV628763 1.0 ug DNA
EUR 1626

CENPT Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV664134 1.0 ug DNA
EUR 818.4

CENPI Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV661482 1.0 ug DNA
EUR 1626

CENPQ Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV662124 1.0 ug DNA
EUR 616.8

CENPL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV669048 1.0 ug DNA
EUR 818.4

CENPL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV669054 1.0 ug DNA
EUR 818.4

CENPJ Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV702087 1.0 ug DNA
EUR 540

CENPJ Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV702091 1.0 ug DNA
EUR 540

CENPA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV708615 1.0 ug DNA
EUR 379.2

CENPA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV708619 1.0 ug DNA
EUR 379.2

CENPW Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV700848 1.0 ug DNA
EUR 616.8

CENPN Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV662652 1.0 ug DNA
EUR 818.4

CENPO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV791311 1.0 ug DNA
EUR 379.2

CENPC1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV628764 1.0 ug DNA
EUR 1626

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6564006 1.0 ug DNA
EUR 200.4

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6564007 1.0 ug DNA
EUR 200.4

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6564008 1.0 ug DNA
EUR 200.4

CENPJ Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV702092 1.0 ug DNA
EUR 540

CENPA Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV708620 1.0 ug DNA
EUR 379.2

CENPIP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV720971 1.0 ug DNA Ask for price

CENPIP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV720975 1.0 ug DNA Ask for price

CENPO Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV791312 1.0 ug DNA
EUR 379.2

CENPC1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)

LV758915 1.0 ug DNA Ask for price

CENPC1P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV758919 1.0 ug DNA Ask for price

CENPK sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0432506 1.0 ug DNA
EUR 200.4

CENPK sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0432507 1.0 ug DNA
EUR 200.4

CENPK sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0432508 1.0 ug DNA
EUR 200.4

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3101506 1.0 ug DNA
EUR 200.4

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3101507 1.0 ug DNA
EUR 200.4

Cenpk sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3101508 1.0 ug DNA
EUR 200.4

CENPIP1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV720976 1.0 ug DNA Ask for price

Cenpk 3'UTR GFP Stable Cell Line

TU252175 1.0 ml Ask for price

Cenpk 3'UTR GFP Stable Cell Line

TU153719 1.0 ml Ask for price

CENPK 3'UTR GFP Stable Cell Line

TU054223 1.0 ml
EUR 1672.8

CENPC1P1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV758920 1.0 ug DNA Ask for price

CENPT Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV664130 1.0 ug DNA
EUR 818.4

CENPI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV661478 1.0 ug DNA
EUR 1626

CENPQ Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV662120 1.0 ug DNA
EUR 616.8

CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV669044 1.0 ug DNA
EUR 818.4

CENPL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV669050 1.0 ug DNA
EUR 818.4

CENPW Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV700844 1.0 ug DNA
EUR 616.8

CENPN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV662648 1.0 ug DNA
EUR 818.4

Rat Centromere protein K(CENPK) ELISA kit

E02C0931-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Rat Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Rat Centromere protein K(CENPK) ELISA kit

E02C0931-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Rat Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Rat Centromere protein K(CENPK) ELISA kit

E02C0931-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Rat Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Dog Centromere protein K(CENPK) ELISA kit

E08C0931-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Canine Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Dog Centromere protein K(CENPK) ELISA kit

E08C0931-48 1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Canine Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Dog Centromere protein K(CENPK) ELISA kit

E08C0931-96 1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Canine Centromere protein K(CENPK) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Injection of lentivector-loaded hydrogel in vivo led to a sustained stage of transgene expression for greater than two months whereas minimizing the copies of lentivirus genome inserted into the genome of murine skeletal muscle cells. This technique of spatiotemporal management of lentivector supply from alginate hydrogels might present a flexible instrument to mix gene remedy and biomaterials for functions in regenerative medication.

Leave a Reply

Your email address will not be published. Required fields are marked *